Search

Your search keyword '"Jiao, Xiuxiu"' showing total 7 results
Start Over Author "Jiao, Xiuxiu"
7 results on '"Jiao, Xiuxiu"'

1. A tumor microenvironment-responsive micelle co-delivered radiosensitizer Dbait and doxorubicin for the collaborative chemo-radiotherapy of glioblastoma

Author

Zhang, Shuyue, Jiao, Xiuxiu, Heger, Michal, Gao, Shen, He, Mei, Xu, Nan, Zhang, Jigang, Zhang, Mingjian, Yu, Yuan, Ding, Baoyue, Ding, Xueying, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, Pharmaceutics, Afd Pharmaceutics, Sub Membrane Biochemistry & Biophysics, and Pharmaceutics

Subjects
Radiation-Sensitizing Agents, mic-roenvironment-responsive, Brain Neoplasms, Pharmaceutical Science, General Medicine, Chemoradiotherapy, chemo-radiotherapy, Mice, targeted nanotherapeutics, Doxorubicin, Cell Line, Tumor, Tumor Microenvironment, Animals, Humans, radiosensitization, Glioblastoma, Micelles
Abstract

Glioblastoma is rather recalcitrant to existing therapies and effective interventions are needed. Here we report a novel microenvironment-responsive micellar system (ch-K5(s-s)R8-An) for the co-delivery of the radiosensitizer Dbait and the chemotherapeutic doxorubicin (DOX) to glioblastoma. Accordingly, the ch-K5(s-s)R8-An/(Dbait-DOX) micelles plus radiotherapy (RT) treatment resulted in a high degree of apoptosis and DNA damage, which significantly reduced cell viability and proliferation capacity of U251 cells to 64.0% and 16.3%, respectively. The angiopep-2-modified micelles exhibited substantial accumulation in brain-localized U251 glioblastoma xenografts in mice compared to angiopep-2-lacking micelles. The ch-K5(s-s)R8-An/(Dbait-DOX) + RT treatment group exhibited the smallest tumor size and most profound tumor tissue injury in orthotopic U251 tumors, leading to an increase in median survival time of U251 tumor-bearing mice from 26 days to 56 days. The ch-K5(s-s)R8-An/(Dbait-DOX) micelles can be targeted to brain-localized U251 tumor xenografts and sensitize the tumor to chemotherapy and radiotherapy, thereby overcoming the inherent therapeutic challenges associated with malignant glioblastoma.

Published
2022

5. Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous SilicaNanoparticles Loaded with Gboxin for Glioma-targeting Therapy

Author

Jiao, Xiuxiu, Yu, Xiaoyan, Gong, Chunai, Zhu, Hao, Zhang, Bin, Wang, Rong, and Yuan, Yongfang

Abstract

Objective: The purpose of this research is to formulate a biomimetic drug delivery system, which can selectively target glioblastoma (GBM) to deliver the antitumor agent, Gboxin, a novel Complex V inhibitor. Gboxin can specifically inhibit GBM cell growth but not normal cells. Methods: In the present study, we utilized red blood cell (RBC) membrane and U251 cell membrane to obtain a hybrid biomimetic membrane (RBC-U), and prepared RBC-U coated Gboxin-loaded mesoporous silica nanoparticles ((MSNs/Gboxin)@[RBC-U]) for GBM chemotherapy. The zeta potential, particle size, and morphology of (MSNs/Gboxin)@[RBC-U] were characterized. The cellular uptake, effect of cells growth inhibition, biocompatibility, and specific self-recognition of nanoparticles were evaluated. Results: The (MSNs/Gboxin)@[RBC-U] was successfully fabricated and possessed high stability in the circulation system. The drug loading of Gboxin was 13.9%. (MSNs/Gboxin)@ [RBC-U] could effectively retain drugs in the physiological environment and released Gboxin rapidly in the tumor cells. Compared to the MSNs/Gboxin, the (MSNs/Gboxin)@[RBC-U] exhibit highly specific self-recognition to the source cell line. Additionally, the (MSNs/Gboxin) @[RBC-U] showed excellent anti-proliferation efficiency (IC50 = 0.21 μg/mL) in the tumor cell model and few side effects in normal cels in vitro. Conclusion: The (MSNs/Gboxin)@[RBC-U] exhibited significant anti-cancer effects in vitro and the specific self-recognition to GBM cells. Hence, (MSNs/Gboxin)@[RBC-U] could be a promising delivery system for GBM targeted therapy.

Published
2022
Full Text
View/download PDF

7. A tumor microenvironment-responsive micelle co-delivered radiosensitizer Dbait and doxorubicin for the collaborative chemo-radiotherapy of glioblastoma.

Author

Zhang S, Jiao X, Heger M, Gao S, He M, Xu N, Zhang J, Zhang M, Yu Y, Ding B, and Ding X

Subjects
Animals, Cell Line, Tumor, Chemoradiotherapy methods, Doxorubicin, Humans, Mice, Micelles, Tumor Microenvironment, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Glioblastoma drug therapy, Glioblastoma radiotherapy, Radiation-Sensitizing Agents pharmacology
Abstract

Glioblastoma is rather recalcitrant to existing therapies and effective interventions are needed. Here we report a novel microenvironment-responsive micellar system (ch-K5(s-s)R8-An) for the co-delivery of the radiosensitizer Dbait and the chemotherapeutic doxorubicin (DOX) to glioblastoma. Accordingly, the ch-K5(s-s)R8-An/(Dbait-DOX) micelles plus radiotherapy (RT) treatment resulted in a high degree of apoptosis and DNA damage, which significantly reduced cell viability and proliferation capacity of U251 cells to 64.0% and 16.3%, respectively. The angiopep-2-modified micelles exhibited substantial accumulation in brain-localized U251 glioblastoma xenografts in mice compared to angiopep-2-lacking micelles. The ch-K5(s-s)R8-An/(Dbait-DOX) + RT treatment group exhibited the smallest tumor size and most profound tumor tissue injury in orthotopic U251 tumors, leading to an increase in median survival time of U251 tumor-bearing mice from 26 days to 56 days. The ch-K5(s-s)R8-An/(Dbait-DOX) micelles can be targeted to brain-localized U251 tumor xenografts and sensitize the tumor to chemotherapy and radiotherapy, thereby overcoming the inherent therapeutic challenges associated with malignant glioblastoma.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results